ImmunityBio Inc. (NASDAQ: IBRX) faces multiple securities class action lawsuits filed by investors who suffered losses after the company’s stock plummeted 21% on March 24, 2026, following the FDA’s issuance of a warning letter. The FDA cited ImmunityBio for misbranding its lead biopic cancer treatment, Anktiva, in television advertisements and podcasts that allegedly created a misleading impression the drug could cure and prevent all cancer. Shareholders claim the company, led by billionaire investor Patrick Soon-Shiong, made false statements about Anktiva’s true efficacy, concealing regulatory compliance problems that eventually triggered the FDA enforcement action and tanked the stock price.
Multiple law firms including Rosen Law Firm, Robbins LLP, and Kaplan Fox have initiated litigation to recover damages for investors harmed during the class period running from January 19, 2026, through March 24-25, 2026. If you purchased ImmunityBio stock during this period and suffered losses following the FDA warning letter disclosure, you may have the right to participate in this class action and recover a portion of your investment losses. This article explains what happened, what the lawsuit alleges, and the critical deadline for investors seeking to lead the litigation. The case highlights a recurring pattern in securities litigation: overpromising drug efficacy to support stock valuations, only to face regulatory enforcement that wipes out shareholder value in days. ImmunityBio’s experience also underscores how the FDA actively monitors promotional claims made by biopharmaceutical companies and will challenge communications that exceed approved indications.
Table of Contents
- What Did the FDA Warning Letter Allege Against ImmunityBio?
- How Did ImmunityBio’s Alleged Misstatements Affect Investor Confidence?
- Who Is Driving the Lawsuits, and What Are the Critical Deadlines?
- What Steps Should Investors Take to Protect Their Rights and Join the Lawsuit?
- What Should Investors Understand About Securities Class Action Recoveries?
- What Is Anktiva and How Does ImmunityBio’s Regulatory Problem Affect Its Future?
- What Are the Regulatory and Legal Implications for Other Biopharmaceutical Companies?
What Did the FDA Warning Letter Allege Against ImmunityBio?
On March 24, 2026, the FDA issued a warning letter to immunitybio citing “TV ad and podcast” promotional materials for Anktiva that were misbranded in violation of the Federal Food, Drug, and Cosmetic Act. The FDA’s core concern was that ImmunityBio’s promotional communications “create a misleading impression that Anktiva…can cure and even prevent all cancer,” claims that far exceed the drug’s approved indications. This type of violation is taken seriously by regulators because exaggerated efficacy claims can lead patients to forgo proven alternative treatments or delay seeking appropriate care, creating genuine public health risks.
Anktiva is ImmunityBio’s flagship biologic therapy for bladder cancer, but the FDA approval covered a specific indication and patient population—not all cancers, and certainly not cancer prevention. When companies make broader claims in consumer-facing advertising, the agency responds with warning letters as a first enforcement step, often followed by additional remedies if the company does not promptly correct the misstatements. In this case, ImmunityBio’s marketing crossed a clear regulatory line, making claims about a drug’s cancer-curing and cancer-preventing properties that simply were not supported by the approved clinical data. However, if ImmunityBio had made identical claims in peer-reviewed publications or at medical conferences (rather than direct-to-consumer advertising), the regulatory response might have been different—the FDA’s concern was specifically with consumer-facing marketing that could mislead patients.
How Did ImmunityBio’s Alleged Misstatements Affect Investor Confidence?
The class action complaint alleges that Patrick Soon-Shiong and ImmunityBio materially overstated Anktiva’s therapeutic capabilities and efficacy profile, concealing the actual clinical limitations of the drug. These false and misleading statements inflated investor expectations and kept the stock price artificially elevated, because shareholders believed they held a stake in a company with a more broadly applicable, more commercially valuable drug than was actually the case. When the FDA’s warning letter revealed the truth—that Anktiva’s approved use was far narrower than ImmunityBio’s marketing had suggested—the stock reacted violently. On March 24, 2026, ImmunityBio stock fell $1.98 per share, or 21%, closing at $7.42 per share.
For investors who bought at higher prices during the class period (January 19 through March 24, 2026), this one-day collapse crystallized significant losses. A shareholder who purchased 1,000 shares at an average price of $9.00 per share during the class period, for example, lost roughly $1,580 per share or $1,580 total when the stock dropped to $7.42. The FDA warning letter was the catalyst, but shareholders argue the real cause of the loss was ImmunityBio’s earlier misrepresentations that set unrealistic expectations for Anktiva’s market potential. However, it is important to note that not every stock price decline following bad news qualifies for a successful securities class action—the plaintiff must prove that management made materially false statements, that those statements were known to be false or were made with reckless disregard for the truth, and that the false statements directly caused the shareholder losses.
Who Is Driving the Lawsuits, and What Are the Critical Deadlines?
Four major securities litigation firms—Rosen Law Firm, Robbins LLP, Robbins Geller Rudman & Dowd LLP, and Kaplan Fox—have filed separate class actions on behalf of ImmunityBio shareholders. Each firm is seeking a lead plaintiff to represent the class of all investors harmed by the alleged misstatements. The lead plaintiff deadline is May 26, 2026, a date of critical importance to any investor considering participation. If you wish to serve as the lead plaintiff—the shareholder who will work with counsel to oversee the litigation—you must submit documentation of your holdings and losses by this deadline.
Lead plaintiffs do not pay attorneys’ fees out of pocket; rather, fees are recovered from any settlement or judgment at the conclusion of the case. However, the lead plaintiff role carries responsibilities including staying informed about major litigation decisions, potentially testifying at trial, and coordinating with the attorneys. For most class members who do not serve as lead plaintiff, participation is largely passive; you simply receive notice of the settlement terms when one is reached and can opt in or out of the class. If you took losses on ImmunityBio stock and did not receive direct litigation notice from one of the four firms, you can still reach out to them to register as a class member and ensure you are included in any future recovery.
What Steps Should Investors Take to Protect Their Rights and Join the Lawsuit?
If you purchased ImmunityBio stock between January 19, 2026, and March 24-25, 2026, your first step is to gather documentation of your trades, including the dates, quantities, and prices of your purchases and any sales during the class period. You will need this information to calculate your losses and to support any claim to be designated lead plaintiff. Next, contact one or more of the securities law firms handling the case—Rosen Law Firm, Robbins LLP, or Kaplan Fox—to discuss your losses and whether you meet the class definition. The timeline is crucial: May 26, 2026, is the deadline to submit an application to serve as lead plaintiff.
If you miss this deadline, you can still be included in the class as a regular class member, but you will not have a voice in major litigation decisions. Many investors prefer not to serve as lead plaintiff because the role requires time and attention; instead, they simply register their losses with the law firm and wait for the eventual settlement or judgment. When a settlement is reached, class members typically receive a notice explaining claim procedures and settlement terms, and then have a period—often 60 to 90 days—to file a claim form requesting their share of the recovery. A practical comparison: lead plaintiff status gives you influence but requires effort; non-lead class member status is passive but requires you to follow the case timeline to file your claim on time.
What Should Investors Understand About Securities Class Action Recoveries?
Securities class actions are a form of civil litigation designed to compensate shareholders for losses caused by management fraud or misconduct. Unlike individual lawsuits, class actions combine the claims of thousands of shareholders into a single case, which reduces litigation costs per shareholder and makes recovery economical even for modest individual losses. However, investors should understand that class action recoveries are typically partial recoveries, not dollar-for-dollar restitution. Settlement amounts are negotiated between plaintiffs’ counsel and the defendant (or their insurance carriers), and the final amount is divided among all class members in proportion to their losses.
For example, if a securities class action settles for $50 million and the total provable shareholder losses in the class are calculated as $200 million, each class member recovers approximately 25 cents on the dollar. Attorneys’ fees, approved by the court and typically ranging from 25% to 33% of the settlement, are deducted before class member recovery. Additionally, settlement negotiations often resolve claims on terms favorable to defendants—for instance, the defendant may not admit wrongdoing as part of the settlement agreement. A limitation to keep in mind is that some investors, particularly those who used margin accounts or who held the stock in certain derivative positions, may face complications in establishing their losses or may be subject to exclusions from the class definition. It is worth discussing your specific circumstances with the law firm to understand whether you are clearly within the class and how your losses would be calculated.
What Is Anktiva and How Does ImmunityBio’s Regulatory Problem Affect Its Future?
Anktiva (sacituzumab govitecan) is a bispecific monoclonal antibody targeting two molecules on cancer cell surfaces, developed to treat bladder cancer that has become resistant to standard chemotherapy. The drug received FDA approval and was positioned by ImmunityBio as a significant advance in oncology, with the company conducting clinical trials to evaluate its potential in other cancer types. However, the FDA’s regulatory authority is limited to approved indications—if a company conducts a trial for pancreatic cancer or lung cancer, it cannot market Anktiva for those uses until new trials are completed and FDA approval is obtained for those specific indications.
ImmunityBio’s television and podcast advertising apparently violated this foundational regulatory requirement by claiming Anktiva could prevent or cure cancer broadly, rather than limiting claims to its approved indication. For investors, this is a critical reminder that biopharmaceutical valuations are highly dependent on regulatory compliance and clinical data. A drug that appears promising in early trials can still fail in later-stage studies or face insurmountable regulatory barriers. ImmunityBio’s crisis is a case study in how marketing missteps can undermine shareholder value even when the underlying science has merit.
What Are the Regulatory and Legal Implications for Other Biopharmaceutical Companies?
The ImmunityBio case arrives amid heightened FDA scrutiny of direct-to-consumer advertising by biopharmaceutical companies. In recent years, the FDA has issued more warning letters for misleading drug promotions, signaling a shift toward stricter enforcement. For other biopharmaceutical companies with drugs in development or recently approved, the ImmunityBio lawsuit serves as a cautionary tale: promotional claims must be tethered to the approved indication, clinical trial data must be accurately represented, and exaggerated efficacy claims will trigger regulatory and legal consequences.
From a shareholder perspective, the case also reinforces the importance of scrutinizing a company’s regulatory standing before investing in biopharmaceutical stocks. Reviewing the company’s FDA correspondence, clinical trial disclosures, and compliance record is a prudent step when evaluating investment risk. As litigation proceeds, investors and regulators will watch for evidence about what ImmunityBio’s leadership knew regarding the company’s promotional practices and when they became aware of regulatory concerns. If discovery reveals that ImmunityBio received internal warnings about non-compliant marketing before the FDA issued its formal warning letter, the damages exposure for the company could increase significantly.